Article on BioWorld by Trista Morrison Biotech firms have long borrowed ideas from the high tech world. The venture-backed start-up business model on which the entire biotech industry is based came from high tech, and it has served both industries well despite their very different timelines and cost structures. Even so, current capital constraints have … Read More
Author: Christos Andronis
The role of drug repositioning in future drug development
What role is #drugrepositioning to take in future drug development? Interview of Aris Persidis to Total BioPharma’s Matt Turner 5 April 2012 “I see a very significant role for drug repositioning in current and also future drug development. Not only is it driven by the patent cliff, which is not a singular event but a … Read More
Pharmaceutical Engineering interview with Dr. Aris Persidis
Industry Interview Series: Dr. Aris Persidis, President and Co-founder, Biovista, Inc. Online article in Pharmaceutical Engineering Magazine. With patent expirations looming for many major pharmaceutical companies, drug repositioning has become a matter of intense interest during the past few years. Biovista’s President and Co-founder discusses the basics of drug repositioning and the potential impact it … Read More
Health Blog: With Help from Author Laura Hillenbrand, Drug Repurposing Comes to Chronic Fatigue Syndrome
Article by Health Blog’s Amy Dockser Marcus on Biovista’s contribution to CFS research. The CFIDS Association of America says that $2 million in funding — backed by individual gifts including a $250,000 donation from best-selling writer Laura Hillenbrand, who has chronic fatigue syndrome– is going to grants and projects designed to accelerate the development of … Read More
Repurposed drugs and your IP strategy
Using examples of drugs and companies, Dr Andreas Persidis gives tips on how to establish a systematic drug repositioning programme. Online article in the Managing Intellectual Property website. In the absence of productive internal R&D sufficient to support growth, current pharmaceutical IP strategies focus on acquiring smaller biotechs with promising assets to bolster larger pharma’s … Read More